US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US6028190A
(en)
|
1994-02-01 |
2000-02-22 |
The Regents Of The University Of California |
Probes labeled with energy transfer coupled dyes
|
GB9412394D0
(en)
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
US6166024A
(en)
*
|
1995-03-30 |
2000-12-26 |
Mayo Foundation For Medical Education And Research |
Use of topical azathioprine and thioguanine to treat colorectal adenomas
|
US6231888B1
(en)
|
1996-01-18 |
2001-05-15 |
Perio Products Ltd. |
Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
|
FR2745500B1
(fr)
*
|
1996-03-04 |
1998-04-03 |
Synthelabo |
Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
|
KR20000053326A
(ko)
*
|
1996-11-15 |
2000-08-25 |
데이비드 엠 모이어 |
결장내 운반에 사용되는 다층 장용성 중합체 코팅물을 갖는 약제학적 제형
|
US20060029653A1
(en)
*
|
1997-01-29 |
2006-02-09 |
Cronk Peter J |
Therapeutic delivery system
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
DK1135112T3
(da)
*
|
1998-11-27 |
2005-02-14 |
Kanji Takada |
Oral formulering til gastrointestinal lægemiddeladministration
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
US6632451B2
(en)
|
1999-06-04 |
2003-10-14 |
Dexcel Pharma Technologies Ltd. |
Delayed total release two pulse gastrointestinal drug delivery system
|
AU5680100A
(en)
*
|
1999-06-14 |
2001-01-02 |
Cosmo S.P.A. |
Controlled release and taste masking oral pharmaceutical compositions
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
SE0000774D0
(sv)
*
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
SE0000773D0
(sv)
*
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
US6365181B1
(en)
|
2000-04-20 |
2002-04-02 |
Gattefosse Corporation |
Thixatropic gelatin carrier composition
|
WO2001095912A1
(en)
*
|
2000-06-16 |
2001-12-20 |
Mitsubishi Pharma Corporation |
COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED
|
CA2359812C
(en)
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
AU2002305758B2
(en)
*
|
2001-06-01 |
2006-09-07 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
SE0102993D0
(sv)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
MY148805A
(en)
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
CA2515731C
(en)
|
2003-02-12 |
2012-07-24 |
Connetics Australia Pty Ltd |
Sunscreen hydroethanolic foam
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
EP2664337B1
(de)
|
2005-09-27 |
2019-08-14 |
TissueTech, Inc. |
Amnion-Zubereitungen und gereinigte Zusammensetzungen und Anwendungsverfahren
|
US20070098746A1
(en)
*
|
2005-11-02 |
2007-05-03 |
Nichols William M |
Multi-layered coating technology for taste masking
|
US8022054B2
(en)
|
2005-11-28 |
2011-09-20 |
Marinus Pharmaceuticals |
Liquid ganaxolone formulations and methods for the making and use thereof
|
WO2007122478A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Themis Laboratories Private Limited |
Multiple unit compositions
|
US20080014257A1
(en)
*
|
2006-07-14 |
2008-01-17 |
Par Pharmaceutical, Inc. |
Oral dosage forms
|
EP2056818B1
(de)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Zusammensetzungen und verfahren für nervenschutz
|
MX2009002195A
(es)
|
2006-08-30 |
2009-05-28 |
David William Smith |
Metodo para impartir una rigidez mono-axial o multi-axial a materiales extruidos y productos que resultan de los mismos.
|
HUE028086T2
(en)
|
2006-09-22 |
2016-11-28 |
Pharmacyclics Llc |
Bruton tyrosine kinase inhibitors
|
EP2066309B1
(de)
|
2007-04-04 |
2012-08-29 |
Sigmoid Pharma Limited |
Orale pharmazeutische zusammensetzung
|
US20090028944A1
(en)
*
|
2007-07-16 |
2009-01-29 |
Balaji Sathurappan |
Pharmaceutical compositions comprising mesalamine
|
US20090036414A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Mutual Pharmaceutical Company, Inc. |
Mesalamine Formulations
|
US8263641B2
(en)
|
2007-09-10 |
2012-09-11 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
US20090169622A1
(en)
*
|
2007-12-27 |
2009-07-02 |
Roxane Laboratories, Inc. |
Delayed-release oral pharmaceutical composition for treatment of colonic disorders
|
WO2010027875A2
(en)
|
2008-08-27 |
2010-03-11 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
KR20110079641A
(ko)
|
2008-09-09 |
2011-07-07 |
아스트라제네카 아베 |
제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
|
US20100069887A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Multiple chamber ex vivo adjustable-release final dosage form
|
US20100068266A1
(en)
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo-modifiable multiple-release state final dosage form
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
EP2421901B1
(de)
|
2009-04-24 |
2015-10-28 |
Tissue Tech, Inc. |
Zusammensetzungen mit hc-ha-komplex und verfahren zu ihrer verwendung
|
SI2432455T1
(sl)
|
2009-05-18 |
2015-04-30 |
Sigmoid Pharma Limited |
Sestava, obsegajoäśa oljne kapljice
|
SG176724A1
(en)
|
2009-06-25 |
2012-01-30 |
Astrazeneca Ab |
Method for treating a patient at risk for developing an nsaid-associated ulcer
|
EP2464341B1
(de)
|
2009-08-12 |
2022-07-06 |
Sublimity Therapeutics Limited |
Immunmodulatorische zusammensetzungen mit einer polymermatrix und einer ölphase
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
JP2013525448A
(ja)
|
2010-04-27 |
2013-06-20 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
WO2011139489A2
(en)
|
2010-04-27 |
2011-11-10 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
CA2800913C
(en)
|
2010-06-03 |
2019-07-23 |
Pharmacyclics, Inc. |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
CA2802994A1
(en)
|
2010-06-17 |
2011-12-22 |
The United States Of America As Represented By The Secretary, National I Nstitutes Of Health |
Compositions and methods for treating inflammatory conditions
|
AU2011293201B2
(en)
|
2010-08-27 |
2015-11-05 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
ES2822301T3
(es)
|
2011-06-10 |
2021-04-30 |
Tissuetech Inc |
Métodos de procesamiento de tejidos de soporte fetal
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CN103917231B
(zh)
|
2011-09-13 |
2016-09-28 |
药品循环有限责任公司 |
组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
|
CA2860231A1
(en)
|
2011-12-28 |
2013-07-04 |
Pozen Inc. |
Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
MY168791A
(en)
|
2012-01-06 |
2018-12-04 |
Abide Therapeutics Inc |
Carbamate compounds and of making and using same
|
JP2012107058A
(ja)
*
|
2012-02-27 |
2012-06-07 |
Warner Chilcott Co Llc |
複数のコーティングを有する医薬剤形
|
BR112014024159A2
(pt)
|
2012-03-29 |
2017-06-20 |
Therabiome Llc |
Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
|
CN110354132A
(zh)
|
2012-06-04 |
2019-10-22 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶抑制剂的晶形
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック,インク. |
Hc−ha/ptx3複合体を含む組成物およびその使用方法
|
DK2900674T3
(en)
|
2012-09-28 |
2017-07-03 |
Univ Washington Through Its Center For Commercialization |
RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6464142B2
(ja)
|
2013-03-14 |
2019-02-06 |
セラバイオーム,エルエルシー |
プロバイオティクス生物及び/又は治療剤の標的化胃腸管デリバリー
|
EP2953619A1
(de)
|
2013-03-15 |
2015-12-16 |
Warner Chilcott Company, LLC |
Pharmazeutische mesalaminzusammensetzung mit mehrfachdosierungselemente für reduzierte abgabevariabilität
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
JP6165022B2
(ja)
*
|
2013-10-30 |
2017-07-19 |
株式会社ファンケル |
放出制御型ソフトカプセル剤
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
EP3134418A4
(de)
|
2014-04-23 |
2018-01-03 |
The Research Foundation for The State University of New York |
Schnelle und effiziente reaktion zur bioorthogonalen reaktion und borhaltige, zusammen damit nützliche heterocyclen
|
US10570169B2
(en)
|
2014-05-22 |
2020-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
CA2966801A1
(en)
|
2014-11-07 |
2016-05-12 |
Sigmoid Pharma Limited |
Compositions comprising cyclosporin
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
EP3253766B1
(de)
|
2015-02-06 |
2019-09-04 |
University of Washington |
Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20160243288A1
(en)
|
2015-02-23 |
2016-08-25 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
CA2977521C
(en)
|
2015-02-27 |
2024-03-19 |
Curtana Pharmaceuticals, Inc. |
1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
|
AU2016226279B2
(en)
|
2015-03-03 |
2021-11-11 |
Pharmacyclics Llc |
Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MX2017014344A
(es)
|
2015-05-11 |
2018-04-11 |
Abide Therapeutics Inc |
Metodos para el tratamiento de la inflacion o el dolor neuropatico.
|
CN107847526A
(zh)
|
2015-05-20 |
2018-03-27 |
组织技术公司 |
用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
|
US20180185378A1
(en)
*
|
2017-01-05 |
2018-07-05 |
Cormedix Inc. |
Antimicrobial delivery system for the prevention and treatment of infections in the colon
|
US20170209462A1
(en)
|
2015-08-31 |
2017-07-27 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
EP3162362A1
(de)
*
|
2015-10-30 |
2017-05-03 |
Dr. Falk Pharma Gmbh |
Optimierte mesalazinhaltige hochdosistablette
|
JP2019505498A
(ja)
|
2015-12-16 |
2019-02-28 |
ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ |
Nk細胞におけるサイトカイン誘導性sh2タンパク質の阻害
|
WO2017125424A1
(en)
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
MA43649A
(fr)
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprenant un inhibiteur de btk
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
CN116509869A
(zh)
|
2016-04-04 |
2023-08-01 |
希诺皮亚生物科学公司 |
使用曲匹地尔治疗锥体外系综合征
|
JP2019516773A
(ja)
|
2016-05-25 |
2019-06-20 |
コンセントリック アナルジジックス,インク. |
改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールtrpv1アゴニストのプロドラッグ
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
EP3957629B1
(de)
|
2016-07-18 |
2023-09-06 |
Arthrosi Therapeutics, Inc. |
Verfahren zur herstellung von deuteriertem hydroxy-benzbromaron und deren zwischenprodukten
|
JP7028860B2
(ja)
|
2016-08-26 |
2022-03-02 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
WO2018093950A1
(en)
|
2016-11-16 |
2018-05-24 |
Abide Therapeutics, Inc. |
Pharmaceutical formulations
|
PE20191239A1
(es)
|
2016-11-16 |
2019-09-16 |
Abide Therapeutics Inc |
Formas cristalinas de un inhibidor de magl
|
CA3078723A1
(en)
|
2016-11-28 |
2018-05-31 |
Nachiappan Chidambaram |
Oral testosterone undecanoate therapy
|
TWM553193U
(zh)
*
|
2017-06-22 |
2017-12-21 |
Guang De Li Capsules Co Ltd |
耐酸膜衣膠囊結構
|
EP3675865A4
(de)
|
2017-09-01 |
2021-06-02 |
University of Washington |
Kristalline formen von verbindungen zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
EP3830078A4
(de)
|
2018-07-27 |
2022-03-30 |
Concentric Analgesics, Inc. |
Pegylierte prodrugs von phenolischen trpv1-agonisten
|
SG11202106304RA
(en)
|
2018-12-31 |
2021-07-29 |
Biomea Fusion Llc |
Irreversible inhibitors of menin-mll interaction
|
US20220265630A1
(en)
|
2019-03-15 |
2022-08-25 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
JP2022531012A
(ja)
|
2019-05-03 |
2022-07-05 |
アゾーラ セラピューティクス,インコーポレイテッド |
インジゴ及び/又はインジゴ誘導体を含む組成物並びにその使用の方法
|
WO2020243393A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Vta Labs, Llc |
Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
|
CN115427403A
(zh)
|
2020-04-21 |
2022-12-02 |
H.隆德贝克有限公司 |
单酰基甘油脂肪酶抑制剂的合成
|
WO2022133064A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
WO2022150525A1
(en)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma in the treatment of alcohol use disorder
|
EP4337316A1
(de)
|
2021-05-11 |
2024-03-20 |
Awakn Ls Europe Holdings Limited |
Therapeutische aminoindanverbindungen und zusammensetzungen
|
EP4346788A2
(de)
|
2021-06-03 |
2024-04-10 |
Arcadia Medicine, Inc. |
Enantiomere entactogenzusammensetzungen und verfahren zu deren verwendung
|
CA3228627A1
(en)
|
2021-08-11 |
2023-02-16 |
Thomas Butler |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023022912A1
(en)
|
2021-08-20 |
2023-02-23 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|